---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-178568"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:15:26.523133+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology appoints Jotin Marango as COO; grants 400K option tied to strategic transaction

## Summary
- Jotin Marango appointed COO effective July 15, 2024, in addition to his roles as CFO and Head of Corporate Development.
- Salary increased to $470,000 per year.
- Granted option to purchase 400,000 shares vesting upon consummation of a strategic transaction.
- Marango previously served as CFO since April 2022; prior roles at Aptose Biosciences and Roth Capital.

## SEC filing metadata
- accession: 0001193125-24-178568
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312524178568/0001193125-24-178568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312524178568/d646925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-178568
- JSON: https://secwatch.observer/filing/0001193125-24-178568.json
- Plain text: https://secwatch.observer/filing/0001193125-24-178568.txt

## Key facts
- Executive change
  Jotin Marango was appointed as Chief Operating Officer at ImageneBio, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312524178568/0001193125-24-178568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.